242 related articles for article (PubMed ID: 15231048)
1. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M
J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of St John's wort in depression : what is known?
Butterweck V
CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
[TBL] [Abstract][Full Text] [Related]
3. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
[TBL] [Abstract][Full Text] [Related]
4. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice.
Hirano K; Kato Y; Uchida S; Sugimoto Y; Yamada J; Umegaki K; Yamada S
J Pharm Pharmacol; 2004 Dec; 56(12):1589-95. PubMed ID: 15563766
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Light Intensity, Temperature, and Nutrients to Enhance the Bioactive Content of Hyperforin and Rutin in St. John's Wort.
Kuo CH; Chou YC; Liao KC; Shieh CJ; Deng TS
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948004
[TBL] [Abstract][Full Text] [Related]
7. Current St John's wort research from mode of action to clinical efficacy.
Müller WE
Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
[TBL] [Abstract][Full Text] [Related]
8. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1.
Singer A; Wonnemann M; Müller WE
J Pharmacol Exp Ther; 1999 Sep; 290(3):1363-8. PubMed ID: 10454515
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
Ng QX; Venkatanarayanan N; Ho CY
J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110
[TBL] [Abstract][Full Text] [Related]
10. St John's wort: Prozac from the plant kingdom.
Di Carlo G; Borrelli F; Ernst E; Izzo AA
Trends Pharmacol Sci; 2001 Jun; 22(6):292-7. PubMed ID: 11395157
[TBL] [Abstract][Full Text] [Related]
11. St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
Kholghi G; Arjmandi-Rad S; Zarrindast MR; Vaseghi S
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):629-642. PubMed ID: 35294606
[TBL] [Abstract][Full Text] [Related]
12. Phytochemical characterization of various St. John's Wort extracts.
Kurth H; Spreemann R
Adv Ther; 1998; 15(2):117-28. PubMed ID: 10180998
[TBL] [Abstract][Full Text] [Related]
13. Effects of standardized extracts of St. John's wort on the single-unit activity of serotonergic dorsal Raphe neurons in awake cats: comparisons with fluoxetine and sertraline.
Fornal CA; Metzler CW; Mirescu C; Stein SK; Jacobs BL
Neuropsychopharmacology; 2001 Dec; 25(6):858-70. PubMed ID: 11750179
[TBL] [Abstract][Full Text] [Related]
14. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.
Barnes J; Anderson LA; Phillipson JD
J Pharm Pharmacol; 2001 May; 53(5):583-600. PubMed ID: 11370698
[TBL] [Abstract][Full Text] [Related]
15. Determination of total hypericins in St. John's wort and herbal medicinal products.
Anyzewska M; Kowalczuk A; Łozak A; Jabłczyńska R; Fijałek Z
Acta Pol Pharm; 2010; 67(6):586-92. PubMed ID: 21229872
[TBL] [Abstract][Full Text] [Related]
16. [Mania during the use of a combination preparation with St. John's wort (Hypericum perforatum)].
Güzelcan Y; Scholte WF; Assies J; Becker HE
Ned Tijdschr Geneeskd; 2001 Oct; 145(40):1943-5. PubMed ID: 11675976
[TBL] [Abstract][Full Text] [Related]
17. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways.
Wonnemann M; Singer A; Müller WE
Neuropsychopharmacology; 2000 Aug; 23(2):188-97. PubMed ID: 10882845
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort.
Wonnemann M; Singer A; Siebert B; Müller WE
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S148-51. PubMed ID: 11518066
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort.
Jakobs D; Hage-Hülsmann A; Prenner L; Kolb C; Weiser D; Häberlein H
J Pharm Pharmacol; 2013 Jun; 65(6):907-15. PubMed ID: 23647684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
